Symposium | Navigating therapeutic options for patients with cytopenic MF
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Symposium | Navigating therapeutic options for patients with cytopenic MF
-
ナレーター：
-
著者：
At the ESH 11th Translational Research Conference: Myeloproliferative Neoplasms, April 24–26, 2026, Estoril, PT, the MPN Hub held a symposium, titled Patient-centered approaches in myelofibrosis: Tailoring treatment for anemia and thrombocytopenia. During the symposium, MPN Hub Steering Committee member Steffen Koschmieder, Uniklinikum RWTH Aachen, Aachen, DE, delivered a presentation on navigating therapeutic options for patients with cytopenic myelofibrosis.
In this presentation, Koschmieder discusses current therapeutic approaches to cytopenic MF, including a review of key data on outcomes with momelotinib, pacritinib, luspatercept, and pelabresib and selinexor in combination with ruxolitinib.
This educational resource is independently supported by GSK. All content is developed by the faculty in collaboration with SES. Funders are allowed no influence
Hosted on Acast. See acast.com/privacy for more information.